報價延遲最少15分鐘:2024/05/02 01:07 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.31/-2.46
|
|
企業價值
140.14M
|
| 資產負債 |
|
每股賬面淨值
2.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/02 01:07 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate,ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. |